THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era Friday, March 6, 2026

COMPOUND WATCH

Petrelintide (amylin analog, Roche/Zealand) [Phase 2] ZUPREME-1 topline: 10.7% mean body weight loss at week 42 vs. 1.7% placebo (p<0.001) | N=493 | BMI 37 kg/m² | Age 48 | 53% female | 98% reached maintenance dose

For context: orforglipron hit 12.4% at 72 weeks, Viking's VK2735 oral hit 12.2% in mid-stage data, Structure's GSBR-1290 hit 11.3% at 36 weeks. Petrelintide's 10.7% at 42 weeks is competitive — and it's a different mechanism, not another GLP-1 crowding a crowded field.

Why the mechanism matters for your stack: Amylin receptor activation restores leptin sensitivity rather than mimicking incretin signaling. No fibrillation at neutral pH = co-formulation with other peptides in a single injection is physically possible. Roche is already planning a combination trial with CT-388 later in 2026. If petrelintide clears Phase 3, you get a once-weekly injectable that stacks cleanly with tirzepatide — one injection, two mechanisms. The gray market will have "petrelintide" vials within 18 months of Phase 3 success. Watch the pipeline now.

Next: ZUPREME-2 (T2D population) topline H2 2026.

Semaglutide — LADA add-on [Retrospective, n=80] Journal of Clinical Endocrinology & Metabolism, March 6. Semaglutide added to insulin in 80 LADA patients: HbA1c ↓ significant, BMI ↓ significant, C-peptide levels rose (suggesting preserved β-cell function). 14 of 68 continuing patients discontinued bolus insulin entirely. 57 received oral semaglutide, 11 injectable.

This is a retrospective study — not an RCT. The C-peptide signal is interesting because LADA is autoimmune-driven β-cell destruction; if semaglutide is genuinely preserving function, that's a different story than metabolic weight loss. What a prospective RCT would need to show: randomized allocation, blinded endpoints, longer follow-up to confirm durability of insulin discontinuation. Until then: directional signal, not practice-changing data. If you're using semaglutide off-label for autoimmune conditions, this is the closest thing to human evidence you have — and it's still retrospective.

BPC-157 [Animal] — zero published human RCTs | TB-500 [Animal] | Thymosin Alpha-1 [Animal/limited human]

RFK Jr.'s February 27 Rogan appearance flagged these for potential reclassification. Still no Federal Register notice. Still no formal rule. Hundreds of thousands of injections weekly, zero human RCT data. The BPC-157 Phase 2 trial (NCT07437547) is the first crack in that wall — see Trial Tracker.

VENDOR SIGNAL

No new Finnrick rating changes, failed HPLC results, or Janoshik disclosures in today's data. Check finnrick.com before your next order — rating drops are the most time-sensitive signal this newsletter tracks.

GenoGenix [Flagged] The FDA's March 3 warning letter to GenoGenix is not a marketing compliance issue. Cited violations: unsanitary conditions, aseptic processing failures. Outcome: 3 patients directed to the ER — symptoms: low blood pressure, uncontrollable shaking, shivers, body aches. GenoGenix was also caught repackaging semaglutide, tirzepatide, and retatrutide (a Lilly pipeline drug not yet FDA-approved), and compounding ineligible substances including 5-Amino-1MQ and NAD+.

GenoGenix had a COA. It had a brand. It had customers who trusted it. Three of them ended up in emergency rooms.

The difference between a [Verified] and [COA Only] vendor isn't bureaucratic — it's the difference between independent HPLC confirmation and a PDF the vendor printed themselves.

The mechanism is straightforward: no independent testing → contamination undetected → endotoxin or sterility failure → systemic reaction. This will happen again.

The other 30 warning letters (marketing violations, not manufacturing): Amble Health, Henry Meds, Willow Health Services, Kin Meds, GoodGirlRx, WeightCare, PharmaZee, Join Josie, FitRx, Genesis Health International, Newman Clinic, Strut Health, Peaks Curative, Lean Rx/SkinnyRx, 24HrDoc, Zeuss, Ivim Services, Viv Health, Aspen Aesthetics/Fifty 410, and additional recipients. The FDA has published all 30 letters at FDA.gov — check your platform's parent company name, not just the brand you know. These are compliance violations, not manufacturing failures — but companies have 15 business days from March 3 to respond before FDA can pursue seizure and injunction. That's a supply disruption risk, not just a legal one.

No research peptide vendor raids or criminal prosecutions confirmed today. Enforcement remains targeted at GLP-1 compounders and telehealth marketers — for now.

TRIAL TRACKER

[NCT07437547] BPC-157 — Acute Hamstring Muscle Strain [Phase 2 | Recruiting | Start: Feb 2, 2026] This is the first registered human RCT for BPC-157. To be precise: it doesn't change BPC-157's evidence grade today — it's still [Animal] until data exists. What it changes is the trajectory. For the first time, there's a registered human trial. If enrollment completes and interim data emerges, the grade moves. Watch NCT07437547 for enrollment updates — that's the leading indicator. The indication is narrow (hamstring strain), but the precedent is not.

[NCT07357415] Retatrutide — Phase 3, Obesity Without T2D [Phase 3 | Recruiting | Start: Jan 24, 2026] Phase 2 showed ~24% body weight loss at 48 weeks — the highest number in the obesity drug pipeline. This Phase 3 will either confirm that or reveal the safety profile that explains why it hasn't been approved yet. Relevant today because GenoGenix was caught illegally repackaging retatrutide — a drug that is not approved, is in Phase 3, and has no legitimate compounding supply chain. If you see "retatrutide" from any compounder or gray-market source before FDA approval, that vial has no legitimate origin. Full stop.

[NCT06662539] Petrelintide ZUPREME-1 [Phase 2 | Complete] Already covered above. 493 humans, randomized, double-blind, placebo-controlled. 10.7% weight loss at 42 weeks. This is not rat data.

THE ODDS

Inflation >3% in 2026: 80% probability ($114,762 volume — Polymarket)

This is the number driving your sourcing calendar. Eighty percent is not a tail risk — it's the base case. Here's the chain: inflation at >3% + a shrinking pool of 503B outsourcing facilities (72 registered as of the current FDA registry, down from a larger pre-enforcement baseline — the directional trend matters more than the precise count) + ongoing enforcement pressure = compounding pharmacy pricing has nowhere to go but up. You're already paying $200–500/month for compounded tirzepatide. Supply-side facility consolidation and enforcement are separate mechanisms from general inflation — both are pushing the same direction. The combined effect is upward pricing pressure, not a mechanical 1:1 CPI pass-through.

Tariffs on Chinese goods: Active, with escalation risk

No Polymarket market directly tracks peptide-relevant China tariffs. Here's the actual math, not a made-up range: a 25% tariff on a $2–5 vial adds $0.50–$1.25 at the factory gate. By the time it clears a U.S. reseller operating at 8–10x markup, the tariff cost is partially absorbed into margin — the consumer-facing impact is likely $3–8 per vial at current gray-market retail prices of $40–80, or roughly 5–15% of your out-of-pocket cost (estimate, no direct market data). If you're stacking multiple compounds monthly, that's $30–80/month in additional exposure at current volumes. Not catastrophic per vial — meaningful across a full protocol. If tariff escalation is your concern, the window before uncertainty resolves is now.

Recession by end of 2026: 32% probability ($515,627 volume — Polymarket)

Below the threshold where discretionary health spending contracts noticeably (industry rule of thumb: above ~40%, people start cutting non-covered compounds). At 32%, the more likely effect is channel shifting — people stay on GLP-1s but move from brand Ozempic ($900+/month) to compounders ($200–500/month) to gray market ($40–80/month). That demand pressure on the compounding tier is already visible in the enforcement wave. If this number crosses 40%, expect gray-market order volume to spike and vendor quality to deteriorate as demand outpaces supply.

SIGNAL VS. NOISE

SIGNAL: Petrelintide ZUPREME-1 — 10.7% weight loss, amylin mechanism [Phase 2] 493 humans, randomized, double-blind, placebo-controlled. The amylin mechanism is genuinely differentiated from GLP-1. The 98% tolerability rate is unusually clean. The no-fibrillation property means co-formulation is physically possible. Competitive with the oral field (orforglipron 12.4%/72 weeks, VK2735 12.2%, GSBR-1290 11.3%/36 weeks) on a different mechanism. Reuters has the full competitive landscape.

SIGNAL: GenoGenix manufacturing failure → 3 ER visits Not a labeling problem. Aseptic processing failures, unsanitary conditions, real patients with documented adverse events. This is what happens when [COA Only] operates without independent verification.

SIGNAL: BPC-157 Phase 2 trial now recruiting [still graded Animal until data] NCT07437547 is the first registered human RCT for BPC-157. Evidence grade unchanged today. Trajectory changed permanently.

NOISE: RFK Jr. peptide reclassification "in coming weeks" Per Inc.com: announced on a podcast February 27. No Federal Register notice. No formal rule. Dr. Gillian Goddard (NYU): "Most studies are in rats or even C. elegans worms." Even if reclassification happens, "legal to compound" ≠ "approved" ≠ "tested for purity in your specific vial." Don't change your sourcing strategy based on a Rogan appearance.

NOISE: Oral GLP-1 pill "revolution" will kill the injectable gray market Novo's oral Wegovy is launched. Lilly's orforglipron is expected Q2 2026 — STAT News says "as early as this month", Lilly's CFO and Reuters say "as early as Q2." The STAT timeline is typically closer to FDA action dates than corporate CFO guidance — weight the STAT signal more heavily, but watch for an FDA action date to resolve the discrepancy. Either way: orforglipron works because it's a non-peptide small molecule, not because oral peptide delivery is solved. The injectable gray market isn't ending — it's being stress-tested.

REGULATORY RADAR

30 warning letters, March 3, 2026 — second major enforcement wave since September 2025. FDA Commissioner Makary: "a new era" of proactive enforcement. Warning letter volume in the past 6 months exceeds the entire prior decade. Two distinct violation categories:

Category 1 — Marketing violations (most of the 30): Implying "sameness" with FDA-approved products, obscuring actual compounder identity. Compliance problem → supply disruption risk for your platform.

Category 2 — Manufacturing violations (GenoGenix): Unsanitary conditions, aseptic processing failures, 3 ER visits, illegal retatrutide repackaging, ineligible substances (5-Amino-1MQ, NAD+). Safety problem → reason independent verification exists.

Separately: Novo Nordisk received an FDA untitled letter over its "Only One Ozempic" TV campaign for lack of clinical data supporting superiority claims. Hims & Hers (HIMS) traded lower March 3 following the warning letter announcement, after a prior-session gain of >13% — the stock remains a real-time proxy for FDA enforcement sentiment. No Hims-Novo deal update confirmed today.

RFK reclassification: Still a podcast announcement. Wellworthy and Newser confirm BPC-157 and Thymosin Alpha-1 as reinstatement targets. Until a Federal Register notice appears, treat as directional, not actionable.

WHAT TO WATCH

March 18 (15 business days from March 3): Warning letter response deadline for all 30 telehealth GLP-1 compounders. Action: Identify your compounder's parent company, check the FDA warning letter database, and have a backup compounder identified before the deadline — not after a supply suspension notice.

"As early as this month" / Q2 2026: Orforglipron FDA approval. STAT's "this month" vs. Reuters/Lilly CFO's "Q2" is an unresolved discrepancy — watch for an FDA action date announcement. If approved at Lilly's projected $149–$399/month cash-pay price, that resets the compounding value proposition entirely.

H2 2026: ZUPREME-2 topline (petrelintide in T2D/overweight). If it replicates ZUPREME-1, the amylin mechanism becomes a serious pipeline story and the co-formulation angle becomes commercially real.

Coming weeks (per RFK Jr.): FDA decision on peptide reclassification. The only signal that counts is a Federal Register notice — not a podcast, not a press release.

Ongoing: BPC-157 Phase 2 enrollment (NCT07437547). First interim data will be the most significant evidence development in the gray-market peptide space in years. Enrollment pace is the leading indicator — watch for updates.

The oral GLP-1 pill era is beginning. The injectable gray market isn't ending — it's being stress-tested. The vendors who survive this enforcement cycle will be the ones with independent verification. The ones who don't will have customers in ERs.

Reply to this email with feedback — vendor intel, sourcing questions, protocol data you want graded.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $5/month.